BrainStorm Cell Therapeutics Launches into Next Phase with the Lease of New R&D Facility and Office Space
Related News: Stem Cell Companies, Stem Cell InvestmentBrainStorm Cell Therapeutics Ltd. (BrainStorm), the Israeli subsidiary of BrainStorm Cell Therapeutics Inc. (OTC Bulletin Board: BCLI), an emerging company in the cell therapy space, has announced that it has leased new space in Kiryat Ha'Mada Ve Ha'Technologia in Petach Tikva, Israel.
The new space will be used as a research and development facility, as well as for the corporate offices...
"This is truly a milestone for BrainStorm -- we are refocusing our activities from the research activities on the campus of Tel Aviv University, onto development efforts in an industrial setting," said Yaffa Beck, President and CEO of BrainStorm Therapeutics.
Yet, the choice of the Petach Tikva will enable the Company to keep abreast of the research sponsored at the nearby Felsenstein Medical Research center of the Tel Aviv University.
"Our new location allows us to remain incredibly close to the scientific team, while still giving us the room that we need to grow and evolve as a company."
The company intends to move into the new 600 sq. meter space at the end of Q1, 2005. The facility, which is to be constructed in compliance with regulatory guidelines, is expected to meet company needs as it moves into clinical trials and will include research laboratories, clean rooms for cell processing, and offices.
Posted on February 22, 2005 01:50 PM